Teva Pharmaceutical Industries (NYSE:TEVA) announces positive
results from two Phase 2/3 clinical trials in Japan evaluating Ajovy
(fremanezumab) in patients with chronic and episodic migraine.
The studies met the primary and all secondary endpoints.
Detailed data will be submitted for presentation at future medical conferences and publication.
Otsuka Pharmaceutical Co., Ltd. (OTCPK:OTSKF) is the exclusive licensee in Japan under a May 2017 agreement.
https://seekingalpha.com/news/3537165-tevas-ajovy-successful-in-two-migraine-studies-in-japan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.